DFCM
CLDX icon

Dark Forest Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Dark Forest Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,492
Closed -$98K – 1197
2022
Q3 		$98K Buy
+3,492
New +$107K 0.02% 469

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Dark Forest Capital Management's CLDX Position: Q4 2022 in Review

Dark Forest Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2022, closing a stake of 3,492 shares — an estimated $98K sold.

Dark Forest Capital Management first reported a position in CLDX in Q3 2022 and held it in 1 quarter. The position peaked at $98K in Q3 2022. 168 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

  • Dark Forest Capital Management reported no remaining Celldex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Dark Forest Capital Management sold 3,492 Celldex Therapeutics shares in Q4 2022, an estimated $98K.
  • Dark Forest Capital Management first reported a position in Celldex Therapeutics in Q3 2022 and held it in 1 quarter.
  • Dark Forest Capital Management's Celldex Therapeutics position peaked at $98K in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on Dark Forest Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.